C4X DISCOVERY HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 GBX | +27.32% |
|
+46.79% | +33.33% |
| Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
| Apr. 25 | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
| Sales 2022 | 2.7M 3.39M | Sales 2023 | 1.71M 2.15M | Capitalization | 50.93M 63.91M |
|---|---|---|---|---|---|
| Net income 2022 | -8M -10.04M | Net income 2023 | -11M -13.8M | EV / Sales 2022 | 21.2 x |
| Net cash position 2022 | 4.35M 5.46M | Net cash position 2023 | 3.8M 4.76M | EV / Sales 2023 | 27.6 x |
| P/E ratio 2022 |
-7.51
x | P/E ratio 2023 |
-4.57
x | Employees | 49 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on C4X Discovery Holdings plc
More press releases
| 1 day | +27.32% | ||
| 1 week | +46.79% | ||
| Current month | +24.48% | ||
| 1 month | +24.48% | ||
| 3 months | -6.61% | ||
| 6 months | -18.92% | ||
| Current year | +33.33% |
1 week
8.30
12.00
1 month
7.0012.00
Current year
7.0019.60
1 year
7.0022.00
3 years
7.0047.90
5 years
7.0056.50
10 years
7.00150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Clive Dix
CEO | Chief Executive Officer | 70 | 14-09-02 |
Bradley Hoy
DFI | Director of Finance/CFO | 61 | 16-11-21 |
Nick Ray
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clive Dix
CEO | Chief Executive Officer | 70 | 14-09-02 |
Simon Harford
BRD | Director/Board Member | 64 | 21-04-19 |
| Director/Board Member | 53 | 14-09-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 12 | +27.32% | 3,770,461 |
| 24-04-24 | 9.425 | +4.72% | 1,748,773 |
Delayed Quote London S.E., April 25, 2024 at 11:46 am EDT
More quotes
C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Companyâs pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.
Calendar
2024-12-11
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
| 1st Jan change | Capi. | |
|---|---|---|
| +33.33% | 37.8M | |
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
- Stock Market
- Equities
- C4XD Stock
